VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TLX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TLXTelix Pharmaceuticals Limited
$8.96$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTLXQuarterly Financials

Telix Pharmaceuticals Limited (TLX) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Telix Pharmaceuticals Limited (TLX) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

TLX Income Statement

Quarterly statement

TLX Income Statement

Telix Pharmaceuticals Limited (TLX) annual income statement — 9-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ2'26Q4'25Q2'25Q4'24Q2'24Q4'23Q2'23Q4'22Q2'22Q4'21Q2'21Q4'20Q2'20Q4'19Q2'19Q4'18Q2'18Q4'17Q2'17
Sales/Revenue476.04M410.04M355.14M594.24M188.96M281.71M220.83M136.05M24.05M4.69M2.91M3.61M1.61M1.67M1.82M195K000
Revenue Growth %34.04%-31%87.94%110.94%-14.43%107.07%818.34%2803.31%726.36%29.95%81.08%116.25%-11.58%755.13%-----
Cost of Goods Sold230.48M193.65M182.49M208.45M65.08M57.74M130.02M91.16M39.62M23.54M14.09M11.86M10.23M7.37M7.99M635.75K1.85K3.84K0
COGS % of Revenue48.42%47.23%51.38%35.08%34.44%20.5%58.88%67%164.76%502.43%484.06%328.87%636.65%442.1%439.5%326.03%---
Gross Profit245.55M216.39M172.65M385.8M123.88M223.97M90.81M44.89M-15.57M-18.86M-11.18M-8.25M-8.62M-5.7M-6.17M-440.75K-1.85K-3.84K-52.58K
Gross Margin %51.58%52.77%48.62%64.92%65.56%79.5%41.12%33%-64.76%-402.43%-384.06%-228.87%-536.65%-342.1%-339.5%-226.03%---
Gross Profit Growth %42.23%-43.91%39.37%72.25%36.42%398.93%683.17%338.05%-39.33%-128.5%-29.59%-44.67%-39.76%-1194.28%--11377.86%96.48%--
Operating Expenses259.26M209.9M163.2M317.42M110.13M203.9M59.37M54.59M47.92M31.06M20.42M20.89M11.48M18.37M10.01M17.38M10.46M4.18M1.58M
OpEx % of Revenue54.46%51.19%45.95%53.42%58.28%72.38%26.89%40.13%199.28%662.78%701.86%579.34%714.69%1101.44%551%8911.79%---
Selling, General & Admin135.78M120.97M87.97M111.82M95.3M69.8M28.93M64.02M23.08M10.59M6.75M16.33M2.73M4.9M6.54M5.14M4M1.97M774.63K
SG&A % of Revenue28.52%29.5%24.77%18.82%50.44%24.78%13.1%47.06%95.97%226.06%232.1%452.8%169.77%294%359.98%2635.81%---
Research & Development123.49M88.93M74.22M75.25M45.78M98.4M30.45M33.01M24.84M20.46M13.67M14.48M8.61M13.32M7.84M12.24M6.45M2.2M801.91K
R&D % of Revenue25.94%21.69%20.9%12.66%24.23%34.93%13.79%24.27%103.31%436.73%469.76%401.55%535.47%798.94%431.35%6275.98%---
Other Operating Expenses001000K1000K-1000K1000K0-1000K000-1000K151.85K141.83K-1000K0000
Operating Income-13.71M6.49M9.45M68.38M13.75M22.47M31.44M-9.7M-63.49M-49.92M-31.6M-29.14M-20.11M-24.07M-16.18M-17.19M-10.46M-3.37M-1.58M
Operating Margin %-2.88%1.58%2.66%11.51%7.28%7.98%14.24%-7.13%-264.04%-1065.22%-1085.91%-808.21%-1251.34%-1443.55%-890.5%-8814.39%---
Operating Income Growth %-245.02%-90.51%-31.26%204.31%-56.26%331.55%149.51%80.56%-100.93%-71.27%-57.14%-21.07%-24.25%-40.05%-54.75%-410.6%-563.41%--
EBITDA11.91M18.32M19.04M72.7M17.51M26.18M34.74M-7.05M-60.87M-47.29M-28.79M-26.6M-17.77M-22.16M-13.86M-17.18M-10.46M-3.36M1.58M
EBITDA Margin %2.5%4.47%5.36%12.23%9.27%9.29%15.73%-5.18%-253.14%-1009.13%-989.18%-737.58%-1106.04%-1328.84%-762.67%-8811.79%---
EBITDA Growth %-37.45%-74.81%8.75%177.69%-49.6%471.55%157.07%85.1%-111.47%-77.79%-61.95%-20.03%-28.23%-28.96%-32.56%-411.03%-763.29%--
D&A (Non-Cash Add-back)25.62M11.82M9.59M4.32M3.76M3.71M3.3M2.66M2.62M2.63M2.81M2.55M2.33M1.91M2.32M5.07K1.93K3.84K3.15M
EBIT-13.71M7.29M-1.06M78.46M36.63M19.2M-11.86M-27.65M-70.56M-61.89M-36.69M-34.22M-24.86M-24.35M-16.06M-17.19M-10.46M-4.18M-1.58M
Net Interest Income-2.57M-5.53M-2.35M-6.27M-4.33M18K11K-54K-137K-15K-11K-921K-187K-1.3M-1.01M-437.12K740.86K6.57K35.01K
Interest Income2.27M2.19M010.25M610K566K453K214K1K89K74K19K48K41.58K56.42K164.88K167.87K13.82K39.71K
Interest Expense4.84M7.72M2.35M16.52M4.94M548K442K268K138K104K85K940K235K1.34M1.06M602K-572.98K7.25K4.7K
Other Income/Expense42.88M-6.92M-13.85M-21.46M-4.61M-7.08M-43.74M-18.21M-7.21M-12.08M-5.45M-6.01M-4.99M-1.62M-940.55K6.66M0132.12K5.05K
Pretax Income29.17M-426.46K-4.4M46.91M9.14M15.39M-12.3M-27.92M-70.7M-61.99M-37.05M-35.16M-25.1M-25.69M-17.13M-10.52M-5.19M-3.23M-1.57M
Pretax Margin %6.13%-0.1%-1.24%7.89%4.84%5.46%-5.57%-20.52%-294.02%-1322.94%-1273.06%-974.96%-1561.67%-1540.61%-942.25%-5396.92%---
Income Tax-9.06M4.37M-2.31M8.67M-2.54M-4.14M2.02M5.27M188K-14M-4.53M-8.57M-6.79M-8.19M-6.76M-1.88M-6800
Effective Tax Rate %-31.05%-1023.95%52.61%18.49%-27.75%-26.93%-16.42%-18.87%-0.27%22.58%12.23%24.38%27.08%31.89%39.45%17.9%0%0%0%
Net Income38.22M-4.79M-2.09M38.24M29.37M19.53M-14.32M-33.19M-70.89M-48M-32.51M-26.59M-18.3M-17.5M-10.37M-8.64M-5.19M-4.81M-3.14M
Net Margin %8.03%-1.17%-0.59%6.43%15.54%6.93%-6.48%-24.39%-294.8%-1024.24%-1117.32%-737.27%-1138.83%-1049.33%-570.54%-4430.77%---
Net Income Growth %1933.14%-112.54%-107.1%95.79%305.1%158.85%79.8%30.85%-118.03%-80.53%-77.66%-51.94%-76.49%-102.52%-99.8%-79.79%-65.13%--
Net Income (Continuing)38.22M-4.79M-2.09M38.24M11.68M19.53M-14.32M-33.19M-70.89M-48M-32.51M-26.59M-18.3M-17.5M-10.37M-8.64M-5.19M-3.23M-1.57M
Discontinued Operations0000000000000000000
Minority Interest0000000000000000000
EPS (Diluted)0.11-0.01-0.010.110.030.06-0.05-0.10-0.23-0.17-0.12-0.10-0.07-0.07-0.05-0.04-0.03-0.02-0.02
EPS Growth %--112.82%-118.62%82.42%173.84%160.3%80.39%41.18%-91.67%-70%-66.2%-39.08%-52%-72.01%-80.61%-120%-6.91%--
EPS (Basic)0.11-0.01-0.010.120.030.06-0.05-0.10-0.23-0.17-0.12-0.10-0.07-0.07-0.05-0.04-0.03-0.02-0.02
Diluted Shares Outstanding356.89M338.78M337.2M345.19M350.75M323.73M317.62M316.34M307.33M283.02M281.02M259.95M253.48M243.39M218.37M206.81M197.44M253.52M127.99M
Basic Shares Outstanding339.22M338.78M337.2M331.23M334.23M323.73M317.62M316.34M307.33M283.02M281.02M259.95M253.48M243.39M218.37M206.52M197.44M253.52M127.99M
Dividend Payout Ratio-------------------